What were Rubicon Research Ltd's latest quarterly results?
Rubicon Research Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +92.1% (insufficient_data)
- Revenue Growth YoY: +52.1%
- Operating Margin: 23.0% (expanding)
In , Rubicon Research Ltd (Pharma - Formulators) is outperforming Nifty 500 with +23.2% relative strength. Fundamentals: Average. On a 12-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +52% | +60% | Insufficient Data |
| PAT (Net Profit) | +92% | +61% | Insufficient Data |
| OPM | 23.0% | +100 bps | Expanding |
Based on publicly available financial data. This is educational research, not investment advice.
Rubicon Research Ltd's latest quarterly results (Dec 2025) show
Rubicon Research Ltd's profit is growing with an insufficient_data trend.
Rubicon Research Ltd's revenue growth trend is insufficient_data.
Rubicon Research Ltd's operating margin is expanding.
Rubicon Research Ltd's long-term compounding rates
Rubicon Research Ltd's earnings growth is insufficient_data with strong momentum on a sequential basis.
Rubicon Research Ltd appears significantly overvalued based on our fair value analysis.
Rubicon Research Ltd's current PE ratio is 93.5x.
Rubicon Research Ltd's current PE is 93.5x.
Rubicon Research Ltd's price-to-book ratio is 24.3x.
Rubicon Research Ltd is rated Average with a fundamental score of 54/100. This score is calculated from objective financial metrics
Rubicon Research Ltd has a debt-to-equity ratio of N/A.
Rubicon Research Ltd's return ratios over recent years
Rubicon Research Ltd's operating cash flow is positive (FY2025).
Rubicon Research Ltd currently does not pay a significant dividend (yield 0.00%).
Rubicon Research Ltd's shareholding pattern (Mar 2026)
Rubicon Research Ltd's promoter holding has decreased recently.
Rubicon Research Ltd has been outperforming Nifty 500 for 12 consecutive weeks, indicating strong sustained outperformance.
Rubicon Research Ltd is an established outperformer with 12 weeks of consecutive Nifty 500 outperformance.
Based on quantitative research signals, here is why Rubicon Research Ltd may be worth studying
Rubicon Research Ltd investment thesis summary:
Rubicon Research Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.